말초신경자극기 시장 예측(-2030년)

Peripheral Nerve Stimulator Market Research Report Forecast till 2032

Download PDF

Market Overview

Global Peripheral Nerve Stimulators market is anticipated to register a CAGR of 6.65% during the review period. The Worldwide Peripheral Nerve Stimulators market is encountering a development because of the rising interest for Remote Peripheral Nerve Stimulators. This inclination for cutting edge, remote arrangements in neuromodulation is driving the market forward and showing an extraordinary pattern in medical care. The flood popular features the significant development direction of the market.

The Peripheral nerve feeling as often as possible alluded to as PNS, is a normally utilized way to deal with treat persistent agony. The development of the peripheral nerve stimulators market is ascribed to the rising interest for peripheral nerve stimulators, ascend in instances of nerve wounds, and the developing interest for remote peripheral nerve stimulators. In any case, the absence of specialized abilities for establishment and control of a gadget, and the significant expense related with the peripheral nerve stimulators gadgets is expected to hamper the market development.

The utilization of oral prescriptions like Pamelor, Sinequan, and Elavil in neurological turmoil patients is related with destructive aftereffects and may likewise prompt dependence on drugs. Consequently, the peripheral nerve stimulator is profoundly liked as an elective agony control choice as it gives compelling treatment over oral meds. It decreases the utilization of opiate sedates and can be embedded in patients which permits them to play out their nonimpact sporting exercises like swimming. The Public Organization of Neurological Issues and Stroke reports that around 50 million Americans are impacted by roughly 600 neurologic problems every year. Neuropathic torment is a pervasive medical problem in most industrialized countries, affecting generally 40%-60% of the old populace and grown-ups around the world.

Market Segmentation

The Global Peripheral Nerve Stimulators segmentation, based on products, includes transcutaneous, percutaneous, and implantable.

Based on device type the market is classified into stimulators, continuous peripheral nerve blocks (CPNB) catheters, and pain pumps.

Based on stimulating machines the Global Peripheral Nerve Stimulators market is divided into stimulator machines with train of four (TOF) monitoring features and machines without TOF features. The end use segment is segmented into hospitals & clinics, ambulatory surgery centers, and others.

Region Insights

The viewpoint for the North America Peripheral Nerve Stimulators market stays promising, with supported development expected. Interests in medical care foundation and a developing consciousness of cutting-edge clinical arrangements are supposed to drive market extension further. Both laid out players and arising contestants are ready to exploit these valuable open doors, utilizing mechanical progressions to satisfy the rising need for further developed nerve stimulators results.

Europe Peripheral Nerve Stimulators market represented the second-biggest portion of the overall industry because of innovation progressions, expanding medical services use, and expanding instances of nerve wounds.

The Asia-Pacific Peripheral Nerve Stimulators market is attributable to register a biggest market owing to a high quiet populace, rising number neurovascular infections, and good administrative strategies. Besides, central members working in the Worldwide Peripheral Nerve Stimulators market are effectively venturing into this region, further driving the regional market development.

Major Players

The major companies operating in the Peripheral Nerve Stimulators in market are Braun SE (Germany), MEDTRONIC (Ireland), Boston Scientific Corporation (US), SPR Therapeutics (US), AVNS (US), Teleflex Incorporated (US), Curonix LLC (US), SUNMED (US), Xavant Technology (Pty) Ltd (South Africa), and Vygon (France).

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 EXECUTIVE SUMMARY

• 2.1 OVERVIEW

3 MARKET INTRODUCTION

• 3.1 DEFINITION
• 3.2 SCOPE OF THE STUDY
• 3.3 RESEARCH OBJECTIVE
• 3.4 MARKET STRUCTURE
• 3.5 ASSUMPTIONS & LIMITATIONS

4 RESEARCH METHODOLOGY

• 4.1 DATA MINING
• 4.2 SECONDARY RESEARCH
• 4.3 PRIMARY RESEARCH
• 4.4 BREAKDOWN OF PRIMARY RESPONDENTS
• 4.5 FORECASTING TECHNIQUES
• 4.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
  • 4.6.1 BOTTOM-UP APPROACH
  • 4.6.2 TOP-DOWN APPROACH
• 4.7 DATA TRIANGULATION
• 4.8 VALIDATION

5 MARKET DYNAMICS

• 5.1 OVERVIEW
• 5.2 DRIVERS
  • 5.2.1 INCREASING DEMAND FOR PERIPHERAL NERVE STIMULATORS
  • 5.2.2 RISE IN CASES OF NERVE INJURIES
  • 5.2.3 GROWING DEMAND FOR WIRELESS PERIPHERAL NERVE STIMULATORS
• 5.3 RESTRAINTS
  • 5.3.1 LACK OF TECHNICAL SKILLS FOR INSTALLATION AND CONTROL OF A DEVICE
  • 5.3.2 HIGH COST ASSOCIATED WITH THE PERIPHERAL NERVE STIMULATORS DEVICES
• 5.4 OPPORTUNITIES
  • 5.4.1 GROWING TECHNOLOGICAL ADVANCEMENTS

6 MARKET FACTOR ANALYSIS

• 6.1 VALUE CHAIN ANALYSIS
  • 6.1.1 R&D & DESIGNING
  • 6.1.2 MANUFACTURING
  • 6.1.3 DISTRIBUTION & SALES
  • 6.1.4 POST-SALES MONITORING
• 6.2 PORTER'S FIVE FORCES MODEL
  • 6.2.1 THREAT OF NEW ENTRANTS
  • 6.2.2 BARGAINING POWER OF SUPPLIERS
  • 6.2.3 THREAT OF SUBSTITUTES
  • 6.2.4 BARGAINING POWER OF BUYERS
  • 6.2.5 INTENSITY OF RIVALRY
• 6.3 IMPACT OF COVID-19 ON THE GLOBAL PERIPHERAL NERVE STIMULATORS MARKET
  • 6.3.1 IMPACT ON SUPPLY CHAIN
  • 6.3.2 IMPACT ON PRICING
  • 6.3.1 IMPACT ON REGIONS
  • 6.3.2 IMPACT ON PRODUCTION
  • 6.3.3 IMPACT ON DEMAND-SUPPLY GAP

7 GLOBAL PERIPHERAL NERVE STIMULATORS MARKET, BY PRODUCT

• 7.1 OVERVIEW
• 7.2 TRANSCUTANEOUS
• 7.3 PERCUTANEOUS
• 7.4 IMPLANTABLE

8 GLOBAL PERIPHERAL NERVE STIMULATORS MARKET, BY DEVICE TYPE

• 8.1 OVERVIEW
• 8.2 STIMULATORS
• 8.3 CPNB CATHETERS
• 8.4 PAIN PUMPS
• 8.5 OTHERS

9 GLOBAL PERIPHERAL NERVE STIMULATORS MARKET, BY STIMULATING FEATURE

• 9.1 OVERVIEW
• 9.2 STIMULATOR MACHINES WITH TRAIN OF FOUR (TOF) MONITORING FEATURES
• 9.3 MACHINES WITHOUT TOF FEATURES

10 GLOBAL PERIPHERAL NERVE STIMULATORS MARKET, BY END USER

• 10.1 OVERVIEW
• 10.2 HOSPITAL & CLINICS
• 10.3 AMBULATORY SURGERY CENTERS
• 10.4 OTHERS

11 GLOBAL PERIPHERAL NERVE STIMULATORS MARKET, BY REGION

• 11.1 OVERVIEW
• 11.2 NORTH AMERICA
  • 11.2.1 NORTH AMERICA
  • 11.2.2 US
  • 11.2.3 CANADA
• 11.3 EUROPE
  • 11.3.1 GERMANY
  • 11.3.2 FRANCE
  • 11.3.3 UK
  • 11.3.4 ITALY
  • 11.3.5 SPAIN
  • 11.3.6 REST OF EUROPE
• 11.4 ASIA-PACIFIC
  • 11.4.1 CHINA
  • 11.4.2 INDIA
  • 11.4.3 JAPAN
  • 11.4.4 SOUTH KOREA
  • 11.4.5 AUSTRALIA
  • 11.4.6 REST OF ASIA-PACIFIC
• 11.5 REST OF THE WORLD
  • 11.5.1 MIDDLE EAST
  • 11.5.2 AFRICA
  • 11.5.3 LATIN AMERICA
• 12.1 OVERVIEW
• 12.2 COMPETITIVE BENCHMARKING
• 12.3 MAJOR GROWTH STRATEGY IN THE GLOBAL PERIPHERAL NERVE STIMULATORS MARKET
• 12.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL PERIPHERAL NERVE STIMULATORS MARKET
• 12.5 KEY DEVELOPMENT ANALYSIS
• 12.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
  • 12.6.1 PRODUCT APPROVAL AND PRODUCT LAUNCH
• 12.7 FINANCIAL MATRIX
  • 12.7.1 SALES (USD MILLION), 2021
  • 12.7.2 RESEARCH & DEVELOPMENT EXPENDITURE (USD MILLION), 2021

13 COMPANY PROFILES

• 13.1 MEDTRONIC
  • 13.1.1 COMPANY OVERVIEW
  • 13.1.2 FINANCIAL OVERVIEW
  • 13.1.3 PRODUCTS OFFERED
  • 13.1.4 KEY DEVELOPMENTS
  • 13.1.5 SWOT ANALYSIS
  • 13.1.6 KEY STRATEGIES
• 13.2 B. BRAUN SE
  • 13.2.1 COMPANY OVERVIEW
  • 13.2.2 FINANCIAL OVERVIEW
  • 13.2.3 PRODUCTS OFFERED
  • 13.2.4 KEY DEVELOPMENTS
  • 13.2.5 SWOT ANALYSIS
  • 13.2.6 KEY STRATEGIES
• 13.3 BOSTON SCIENTIFIC CORPORATION
  • 13.3.1 COMPANY OVERVIEW
  • 13.3.2 FINANCIAL OVERVIEW
  • 13.3.3 PRODUCTS OFFERED
  • 13.3.4 KEY DEVELOPMENTS
  • 13.3.5 SWOT ANALYSIS
  • 13.3.6 KEY STRATEGIES
• 13.4 CURONIX LLC
  • 13.4.1 COMPANY OVERVIEW
  • 13.4.2 FINANCIAL OVERVIEW
  • 13.4.3 PRODUCTS OFFERED
  • 13.4.4 KEY DEVELOPMENTS
  • 13.4.5 KEY STRATEGIES
• 13.5 SPR THERAPEUTICS
  • 13.5.1 COMPANY OVERVIEW
  • 13.5.2 FINANCIAL OVERVIEW
  • 13.5.3 PRODUCTS OFFERED
  • 13.5.4 KEY DEVELOPMENTS
  • 13.5.5 KEY STRATEGIES
• 13.6 AVNS
  • 13.6.1 COMPANY OVERVIEW
  • 13.6.2 FINANCIAL OVERVIEW
  • 13.6.3 PRODUCTS OFFERED
  • 13.6.4 KEY DEVELOPMENTS
  • 13.6.5 SWOT ANALYSIS
  • 13.6.6 KEY STRATEGIES
• 13.7 TELEFLEX INCORPORATED
  • 13.7.1 COMPANY OVERVIEW
  • 13.7.2 FINANCIAL OVERVIEW
  • 13.7.3 PRODUCTS OFFERED
  • 13.7.4 KEY DEVELOPMENTS
  • 13.7.5 SWOT ANALYSIS
  • 13.7.6 KEY STRATEGIES
• 13.8 SUNMED
  • 13.8.1 COMPANY OVERVIEWS
  • 13.8.2 FINANCIAL OVERVIEW
  • 13.8.3 PRODUCTS OFFERED
  • 13.8.4 KEY DEVELOPMENTS
  • 13.8.5 KEY STRATEGIES
• 13.9 XAVANT TECHNOLOGY (PTY) LTD
  • 13.9.1 COMPANY OVERVIEW
  • 13.9.2 FINANCIAL OVERVIEW
  • 13.9.3 PRODUCTS OFFERED
  • 13.9.4 KEY DEVELOPMENTS
  • 13.9.5 KEY STRATEGIES
• 13.10 VYGON
  • 13.10.1 COMPANY OVERVIEW
  • 13.10.2 FINANCIAL OVERVIEW
  • 13.10.3 PRODUCTS OFFERED
  • 13.10.4 KEY DEVELOPMENTSS
  • 13.10.5 KEY STRATEGIES

14 APPENDIX

• 14.1 REFERENCES
• 14.2 THE FOUNDATION FOR PERIPHERAL NEUROPATHY
• 14.3 PERIPHERAL NERVE SOCIETY (PNS)
• 14.4 AMERICAN NEUROLOGICAL ASSOCIATION (ANA)
• 14.5 AMERICAN ASSOCIATION OF NEUROLOGICAL SURGEONS
• 14.6 AMERICAN SOCIETY FOR PERIPHERAL NERVE (ASPN)
• 14.7 BRITISH PERIPHERAL NERVE SOCIETY (BPNS)
• 14.8 PAN AFRICAN ASSOCIATION OF NEUROLOGICAL SCIENCES (PAANS)
• 14.9 THE NEUROLOGICAL ASSOCIATION OF SOUTH AFRICA (NASA)
• 4.12 RELATED REPORTS